Arrowhead Pharmaceuticals Inc $ 59.21 -2.48 (-4.02%)
Warning! GuruFocus has detected 2 Severe warning signs with ARWR. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Arrowhead Pharmaceuticals Inc () from 1997 to Oct 28 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Arrowhead Pharmaceuticals stock (ARWR) PE ratio as of Oct 28 2020 is 0. More Details
Arrowhead Pharmaceuticals PE Ratio (TTM) Historical Data
View and export this data going back to 1997. Start your Free Trial
Arrowhead Pharmaceuticals PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:AGIO NAS:BLUE NAS:CCXI NAS:BPMC NAS:ALLK NYSE:BHVN NAS:HALO NAS:PTCT NAS:DCPH NAS:VIR OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.